{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Baseline - Amplitude response - Right Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Baseline - Amplitude response - Left Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"8 weeks - Amplitude response - Right Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"8 Weeks - Amplitude response - Left Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Baseline - Onset Latency response - Right Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Baseline - Onset Latency response - Left Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"8 weeks - Onset Latency response - Right Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"8 weeks - Onset Latency response - Left Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Baseline - Peak Latency response - Right Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Baseline - Peak Latency response - Left Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"8 weeks - Peak Latency response - Right Sural ANKLE (Calf)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"8 weeks - Peak Latency response - Left Sural ANKLE (Calf)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Sural sensory response (collected as yes/no) measured on both the left and right ankles at baseline and 8 weeks for amplitude, onset latency, and peak latency. Reported are the number with sural sensory response measured (yes).","groups":[{"description":"VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG000","title":"Grade 2-3 Established Neuropathy"},{"description":"VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG001","title":"Grade 1-2 New-onset Neuropathy"}],"paramType":"NUMBER","populationDescription":"The number at each timepoint/side is different due to loss in follow-up, patient refusal, and measurement difficulties leading to missing data.","reportingStatus":"POSTED","timeFrame":"Baseline, 8 weeks","title":"Sensory Response Evaluability at Baseline and 8 Weeks","type":"SECONDARY","unitOfMeasure":"number patients"}